Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL104832 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL146219 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL8450321 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL3874905 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL22289019 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL23581850 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL17536594 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL6904662 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL7153075 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL4374385 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090498-A1 | ENCAPSULATED MEDIUM CHAIN FATTY ACID SALTS AND ORAL SOLID DOSAGE FORMS DERIVED THEREFROM | ISP INVESTMENTS LLC (US) | 2025-05-01 | — | — | WO | claimed |
| US-20230149312-A1 | MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE | HERCULES LLC (US) | 2023-05-18 | — | — | US | claimed |
| CN-115996718-A | Modified release pharmaceutical formulation comprising hydroxypropyl cellulose | 赫尔克里士有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4142718-A1 | MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE | Hercules LLC (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2021222369-A1 | MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE | HERCULES LLC (US) | 2021-11-04 | — | — | WO | claimed |
| WO-2025090498-A1 | ENCAPSULATED MEDIUM CHAIN FATTY ACID SALTS AND ORAL SOLID DOSAGE FORMS DERIVED THEREFROM | ISP INVESTMENTS LLC (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024262353-A1 | COMPOSITION FOR ORAL CAVITY | ライオン株式会社 | 2024-12-26 | — | — | WO | disclosed |
| US-20240417384-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12134607-B2 | Crystals of tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-05 | — | — | US | disclosed |
| US-20230149312-A1 | MODIFIED RELEASE PHARMACEUTICAL FORMULATION COMPRISING HYDROXYPROPYL CELLULOSE | HERCULES LLC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115996718-A | Modified release pharmaceutical formulation comprising hydroxypropyl cellulose | 赫尔克里士有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-8568787-B2 | Hydroxyalkylcellulose microparticles | NIPPON SODA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20120232167-A1 | HYDROXYALKYLCELLULOSE MICROPARTICLES | NIPPON SODA CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-2492284-A1 | HYDROXYALKYLCELLULOSE MICROPARTICLES | Nippon Soda Co., Ltd. (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-0607459-B1 | USE OF A SOLID MATERIAL AS A STATIONARY PHASE FOR CHROMATOGRAPHY | KANTO KAGAKU (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-6284288-B1 | Use of silica as agent for controlling the degradation of bicarbonate, resulting mixture and its application | NOVACARB (FR) | 2001-09-04 | — | — | US | disclosed |
| US-5830500-A | FAST DISSOLVING; BLEND CONTAINING DICALCIUM PHOSPHATEDIHYDRATE | PENTECH PHARMACEUTICALS, INC. (US) | 1998-11-03 | — | — | US | disclosed |
| US-5728463-A | Stationary phase material for chromatography | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0607459-A1 | MATERIAL OF CHROMATOGRAPHIC STATIONARY PHASE | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417384-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | ULK2, UTS2R, UMPS | CA2 3467/4885SLC34A1 905/4885KDM4E 410/4885 |
| US-12134607-B2 | Crystals of tetrahydronaphthyl urea derivative | ULK2, UTS2R, UMPS | CA2 3467/4885SLC34A1 905/4885KDM4E 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.